Concepedia

Moacyr Oliveira

MO

Statistics

Publications

6

Citations

1.6K

H-Index

6

Active since

2011

Affiliations

Dana-Farber Cancer Institute(Current)

WinnMed

University of Colorado Denver

University Hospital Heidelberg

University of California, Los Angeles

Moacyr Oliveira is an author at Dana-Farber Cancer Institute specializing in oncology, pharmacology, and chemotherapy.

Publications per year

2011–2019

6

Publications

6

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Leena Gandhi, D. Ross Camidge, Moacyr Oliveira et al. · Journal of Clinical Oncology · 2011 · 591 citations · Full text

, , +17

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Edward B. Garon et al. · Clinical Cancer Research · 2012 · 551 citations · Full text

, , +17

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

, , +12

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira et al. · Clinical Cancer Research · 2013 · 91 citations

, , +17

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

Edward B. Garon, Jeffrey D. Neidhart, Nashar Y Gabrail et al. · OncoTargets and Therapy · 2016 · 58 citations · Full text

, , +13

1–5 of 6